Encouraging results from phase 1/2 COVID-19 vaccine trials

Type Journal Article Author Naor Bar-Zeev Author William J. Moss URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31611-1/abstract Series Comment Volume 396 Issue 10249 Pages 448-449 Publication The Lancet ISSN 0140-6736, 1474-547X Date 20/07/2020 Extra Publisher: Elsevier PMID: 32702300 Journal Abbr The Lancet DOI 10.1016/S0140-6736(20)31611-1 Library Catalog www.thelancet.com Language English Abstract Dystopian realities generate utopian visions. The dramatic emergence of SARS-CoV-2 into our lives and the subsequent COVID-19 pandemic have spawned the active development of nearly 200 vaccine candidates.1 Science reveals itself to the world in real time in all its glorious uncertainties, but also in all its careful, hard-won, and real achievements. As COVID-19 vaccine trials progress rapidly and with much expectation, two such achievements are published in The Lancet.2,3